PMID- 9129221
OWN - NLM
STAT- MEDLINE
DCOM- 19970513
LR  - 20190723
IS  - 0022-202X (Print)
IS  - 0022-202X (Linking)
VI  - 108
IP  - 5
DP  - 1997 May
TI  - Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity.
PG  - 716-20
AB  - Professional antigen-presenting cells (APCs) are required for the initiation of 
      an immune response. Dendritic cells (DCs) are the most potent APCs identified 
      thus far and can present antigen in the context of co-stimulatory signals 
      required for the stimulation of both primed and naive T cells. Cytotoxic T 
      lymphocytes (CTLs) are critical to the immune response against tumors or virally 
      infected cells. Optimal stimulation of antigen-specific CTLs is the goal of 
      evolving immunization strategies for the prevention or therapy of viral 
      infections and tumors. Epidermal dendritic cells (eDCs), or Langerhans cells, can 
      present antigens for the stimulation of CD4+ T cell dependent anti-tumor immunity 
      and may play a role in tumor surveillance. The capacity of eDCs to induce 
      tumor-specific CD8+ CTL immunity has not been determined. We have previously 
      shown that DCs derived from bone marrow precursors (BmDCs) under the influence of 
      cytokines can induce protective, antigen-specific CTL-mediated anti-tumor 
      immunity. Here we show that subcutaneous immunization with ovalbumin (OVA) 
      peptide (SIINFEKL(257-264))-pulsed eDCs induced OVA-specific, CD8+ CTLs that lyse 
      the OVA-expressing target. Furthermore, mice vaccinated with OVA peptide-pulsed 
      eDCs were completely protected from subsequent challenge by the OVA-expressing 
      melanoma MO5. The capacity of peptide-pulsed eDCs to induce CTL-mediated immunity 
      is directly dependent on the dose of eDCs administered. Importantly, the APC 
      capacity of eDCs is comparable to that of BmDCs, as mice immunized with eDC 
      populations containing at least as many class II+/B7.2+ cells as populations of 
      BmDCs were equally protected against challenge with MO5. These results 
      demonstrate that eDCs can be potent inducers of antigen-specific CD8+ 
      CTL-mediated immunity. They suggest that eDCs may be important targets for 
      antigen delivery strategies aimed at inducing antiviral or anti-tumor immunity.
FAU - Celluzzi, C M
AU  - Celluzzi CM
AD  - Department of Dermatology, University of Pittsburgh School of Medicine, 
      Pennsylvania 15213, USA.
FAU - Falo, L D Jr
AU  - Falo LD Jr
LA  - eng
GR  - AR 011884/AR/NIAMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
RN  - 0 (Epitopes)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Membrane Proteins)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Adoptive Transfer
MH  - Animals
MH  - Bone Marrow Cells
MH  - Dendritic Cells/chemistry/cytology/*physiology
MH  - Epitopes
MH  - Female
MH  - Histocompatibility Antigens Class I
MH  - Immunity, Cellular
MH  - Immunization, Passive
MH  - Membrane Proteins/analysis
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasms, Experimental/immunology
MH  - Ovalbumin/pharmacology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured
EDAT- 1997/05/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - S0022-202X(15)42885-4 [pii]
AID - 10.1111/1523-1747.ep12292095 [doi]
PST - ppublish
SO  - J Invest Dermatol. 1997 May;108(5):716-20. doi: 10.1111/1523-1747.ep12292095.